CT-32228

N/A

Report date: 2025/06/11 20:01:15

NME

Base Information

Drug NameCT-32228

Drug Alias Namelysophosphatidic acid acyltransferase-B inhibitors (Cell Therapeutics)LPAAT-B inhibitors (Cell Therapeutics)LPAAT-beta (Cell Therapeutics)CT-32169CT-32458 +[13]

ClassificationSmall molecules

Mechanisms of ActionLysophosphatidic acid acyltransferase inhibitorsApoptosis stimulants

TargetsLysophosphatidic acid acyltransferase

Therapy Area/IndicationsMultiple MyelomaLymphomaLeukemia +[4]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesCti Biopharma Corp

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesCti Biopharma Corp

Active IndicationsN/A

Inactive IndicationsMultiple MyelomaLymphomaLeukemia +[4]

Other Information

ATC CodeN/A